NX Development Corp.

Home
United States
Lexington, KY
NX Development Corp.

Visualizing cancer in a different light. Disclaimer: https://nxdevcorp.com/social-media-disclaimer

Full Social Media Disclaimer: https://go.nxdevcorp.com/socialmedialegaldisclaimer

04/22/2026

Will you be at the Association of Neurological Surgeons Annual Scientific Meeting in San Antonio? Come see us at Booth 856 to connect with our team and learn more about Gleolan®.

04/13/2026

We’re headed to San Antonio! Join the NXDC team at the American Association of Neurological Surgeons 2026 from May 1–3. Stop by Booth 856 to say hello and learn more about Gleolan®

04/06/2026

📢 NX Development Corp. Submits Supplemental New Drug Application to FDA for MEN-301 Study 📝✅

Read the full announcement here:https://nxdevcorp.com/nxdc-com-men-301-submission/ 🌐 🚀

11/27/2025

Wishing everyone a warm and restful Thanksgiving. Our office will be closed on Thursday, November 27, and Friday, November 28. We’ll resume regular business hours on Monday.

07/16/2025

Today, July 16 is Glioblastoma Awareness Day. We pause to honor the strength of those affected by GBM and to amplify the voices calling for better treatments, greater awareness, and lasting change.

06/08/2025

Today we honor patients, caregivers, and healthcare professionals advancing brain tumor care. NXDC joins the global community in recognizing .

05/20/2025

May is Brain Tumor Awareness Month. At NX Development Corp, we stand with the patients, caregivers, and healthcare providers affected by brain tumors. We honor your strength, resilience, and the work being done to advance the understanding of this disease every day.

05/20/2025

🧪 Today we recognize Clinical Trials Day, honoring the patients, clinicians, and researchers who make scientific advancement possible. Clinical trials are the engine of innovation in medicine — and we're proud to be part of the journey toward new hope and better outcomes. Thank you to all those working every day to push discovery forward.

04/26/2025

📢 Meet the NX Development Corp. team at 📍Booth #900! 👋
We’re proud to be part of . 🧠
Learn more: https://nxdevcorp.com/gleolan-updates-2025/

04/26/2025

Excited to join the neurosurgical community at ! Stop by Booth #900 to connect with the NXDC team. 🧠

04/24/2025

Gleolan®(aminolevulinic acid HCl) is now with NX Development Corp., the team that originally brought it to market.
We’re heading to and looking forward to reconnecting with the neurosurgical community. 📍 Booth #900 | April 25–28.

01/11/2025

We’re a Pharmacist in Charge (PIC). Are you a licensed pharmacist in Kentucky with expertise in compliance, cGMP, and regulatory standards? NX Development Corp is seeking a Pharmacist in Charge (PIC) for a remote, part-time contract role requiring only a few hours quarterly.
📜 Requirements:
🎓 Doctor of Pharmacy (Pharm.D.) degree.
📋 2-4 years of experience in pharmacy, quality, and compliance.
🌐 Knowledge of FDA, DEA, and virtual manufacturing regulations.
🚗 Must reside within driving distance of Lexington, Kentucky.
📧 Apply Today!
Send your CV to careers@nxdevcorp.com to join our mission-driven team!

Address

870 Corporate Drive, Suite 403
Lexington, KY
40503

Telephone

+18334536526

Website

https://nxdevcorp.com/

Alerts

Be the first to know and let us send you an email when NX Development Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to NX Development Corp.:

Shortcuts

Want your practice to be the top-listed Clinic in Lexington?

Important Safety Information

Contraindications

Do not use Gleolan in patients with:

· hypersensitivity to aminolevulinic acid (ALA) or porphyrins

· acute or chronic types of porphyria

Warnings and Precautions

Due to the risk of phototoxic reactions, do not administer phototoxic drugs and topical preparations containing ALA for 24 hours during the perioperative period. Reduce exposure to sunlight or room lights for 48 hours after administration of Gleolan.

Errors may occur with the use of Gleolan for intraoperative visualization of malignant glioma, including false negatives and false positives. Non-fluorescing tissue in the surgical field does not rule out the presence of tumor in patients with glioma. Fluorescence may be seen in areas of inflammation or metastases from other tumor types.

Hypersensitivity reactions, including serious hypersensitivity reactions have occurred; these reactions include anaphylactic shock, swelling, and urticaria. Always have cardiopulmonary resuscitation personnel and equipment readily available and monitor all patients for hypersensitivity reactions.

Adverse Reactions

Adverse reactions occurring in >1% of patients in the week following surgery were pyrexia, hypotension, nausea, and vomiting.

Nervous system disorders occurred in 29% of patients within the first week after surgery and events occurring in >1% of patients included: aphasia (8%), hemiparesis (7.8%), hemianopsia (3.2%), headache (2.7%), seizure (1.9%), hemiplegia (1.9%), monoparesis (1.3%) and hypoesthesia (1.1%). Brain edema occurred in

Worsening of >2 Common Toxicity Criteria grades in alanine aminotransferase and gamma-glutamyl transferase occurred in 15.8% and 11.6% of patients, respectively, within the first week after surgery. Absolute levels ranged from 2 times to greater than 10 times the upper limit of normal for each parameter. At 6 weeks, these measurements remained elevated in 2.9% and 7.5% of patients, respectively. There were no cases of liver failure.

Drug-Drug Interactions

See information under Warnings and Precautions regarding phototoxic reactions.

Please see Full Prescribing Information at:https://www.gleolan.com/pdf/prescribing_information.pdf

NX Development Corp.

04/22/2026

04/13/2026

04/06/2026

11/27/2025

07/16/2025

06/08/2025

05/20/2025

05/20/2025

04/26/2025

04/26/2025

04/24/2025

01/11/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Important Safety Information